Markets:

Overview

News

Currencies

International

Treasuries

Vera Therapeutics, Inc. - Class A Common Stock (NQ:VERA)

34.78 +1.13 (+3.36%)

Streaming Delayed Price Updated: 11:00 AM EDT, Jun 12, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Vera Therapeutics, Inc. - Class A Common Stock

< Previous 1 2

...

4 5 6 7 8 9 10 11 Next >

Vera Therapeutics: Q4 Earnings Insights ↗

March 20, 2024

Via Benzinga

Vera Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results

March 20, 2024

From Vera Therapeutics

Via GlobeNewswire

Vera Therapeutics to Participate at the 44th Annual TD Cowen Health Care Conference

February 28, 2024

From Vera Therapeutics

Via GlobeNewswire

$10M Bet On ArriVent BioPharma? Check Out These 4 Stocks Insiders Are Buying ↗

February 02, 2024

Although U.S. stocks closed higher on Thursday, there were a few notable insider trades.

Via Benzinga

(VERA) - Analyzing Vera Therapeutics's Short Interest ↗

January 31, 2024

Via Benzinga

Vera Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

February 02, 2024

From Vera Therapeutics

Via GlobeNewswire

Vera Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares in Public Offering of Class A Common Stock

February 01, 2024

From Vera Therapeutics

Via GlobeNewswire

Vera Therapeutics Announces Pricing of Upsized Public Offering of Class A Common Stock

January 29, 2024

From Vera Therapeutics

Via GlobeNewswire

Vera Therapeutics Announces Proposed Public Offering of Class A Common Stock

January 29, 2024

From Vera Therapeutics

Via GlobeNewswire

Analyst Highlights 'Rock Solid' Data For Vera Therapeutics' Kidney Disease-Targeted Atacicept, Upgrades To Strong Buy ↗

January 26, 2024

72-week data from Vera Therapeutics' Phase 2b ORIGIN trial on atacicept for IgA nephropathy. Analysts upgrade stock to Strong Buy, citing impressive efficacy and low-risk profile.

Via Benzinga

What's Going On With Vera Therapeutics Stock Today? ↗

January 26, 2024

Vera Therapeutics' significant market movements! Discover the latest on atacicept in IgA nephropathy trials, analyst ratings, and FDA approvals.

Via Benzinga

12 Health Care Stocks Moving In Friday's Intraday Session ↗

January 26, 2024

Via Benzinga

Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet (Donald Trump Has Re-Entered The Chat) ↗

January 26, 2024

The Benzinga Stock Whisper Index provides a look at five stocks that saw increased attention from traders over the past week.

Via Benzinga

Topics Government

Why Intel Shares Are Trading Lower By Over 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗

January 26, 2024

Shares of Intel Corporation (NASDAQ: INTC) fell sharply during Friday’s session. Intel reported upbeat results for its fourth quarter, but issued a weak forecast for the first quarter.

Via Benzinga

Booz Allen Hamilton Posts Upbeat Results, Joins AppFolio, Gentex And Other Big Stocks Moving Higher On Friday ↗

January 26, 2024

U.S. stocks traded mixed, with the Dow Jones gaining around 80 points on Friday.

Via Benzinga

Topics Stocks

Nasdaq Edges Lower; American Airlines Posts Upbeat Earnings ↗

January 25, 2024

U.S. stocks traded mixed toward the end of trading, with the Nasdaq Composite turning lower on Thursday. The Dow traded up 0.25% to 37,900.45 while the NASDAQ fell 0.13% to 15,462.53. The S&P 500 also...

Via Benzinga

Topics Stocks

Why Humana Shares Are Trading Lower By Over 11%? Here Are Other Stocks Moving In Thursday's Mid-Day Session ↗

January 25, 2024

Shares of Humana Inc. (NYSE: HUM) fell sharply during Thursday’s session after the company reported fourth-quarter FY23 earnings and issued 2024 guidance.

Via Benzinga

Why Is Immunology Disease Focused Vera Therapeutics Stock Trading Higher Today? ↗

January 25, 2024

Vera Therapeutics' 72-week data from Phase 2b ORIGIN trial on atacicept for IgA nephropathy. Sustained reductions in Gd-IgA1, hematuria, and UPCR, with stable eGFR.

Via Benzinga

Alaska Air Posts Upbeat Earnings, Joins Xerox, United Rentals And Other Big Stocks Moving Higher On Thursday ↗

January 25, 2024

U.S. stocks traded higher, with the Dow Jones gaining around 50 points on Thursday. Shares of Alaska Air Group, Inc. (NYSE: ALK) rose during Thursday’s session following upbeat earnings.

Via Benzinga

Topics Stocks

Crude Oil Rises 2%; Tesla Shares Plunge After Downbeat Results ↗

January 25, 2024

U.S. stocks traded slightly higher midway through trading, with the Nasdaq Composite gaining around 0.2% on Thursday. The Dow traded up 0.06% to 37,829.32 while the NASDAQ rose 0.22% to 15,515.62. The...

Via Benzinga

Topics Stocks

12 Health Care Stocks Moving In Thursday's Intraday Session ↗

January 25, 2024

Via Benzinga

Vera Therapeutics Presents Positive 72-Week Data Showing eGFR Stabilization in the Phase 2b ORIGIN Clinical Trial OLE in IgA Nephropathy

January 25, 2024

From Vera Therapeutics

Via GlobeNewswire

Why Vera Therapeutics Stock Soared by 22% This Week ↗

January 12, 2024

Executive changes and a bullish analyst take combined to boost sentiment on the company.

Via The Motley Fool

Vera Therapeutics Announces Appointment of Industry Veterans Robert Brenner, M.D. as Chief Medical Officer and William D. Turner as Chief Development Officer

January 08, 2024

From Vera Therapeutics

Via GlobeNewswire

Vera Therapeutics to Host In-Person R&D Day in New York to Present Week 72 Data from Phase 2b ORIGIN Clinical Trial of Atacicept in IgAN on January 25, 2024

January 08, 2024

From Vera Therapeutics

Via GlobeNewswire

Vera Therapeutics to Participate in the 42nd Annual J.P. Morgan Healthcare Conference

December 27, 2023

From Vera Therapeutics

Via GlobeNewswire

Calliditas Therapeutics Scores Complete FDA Approval, Broader Label For Lead Kidney Disease Drug ↗

December 21, 2023

The FDA approved Calliditas Therapeutics AB's (NASDAQ: CALT) Tarpeyo (budesonide) delayed-release capsules to reduce the loss of kidney function in adults with primary immunoglobulin A nephropathy...

Via Benzinga

Vera Therapeutics' Kidney Disease Drug Has Opportunity In A Competitive Development Landscape: Analyst ↗

December 18, 2023

Raymond James initiated coverage on Vera Therapeutics Inc (NASDAQ: VERA), a late-stage drug developer in the autoimmune kidney space. The lead asset, atacicept, is a BLyS/APRIL dual inhibitor fusion...

Via Benzinga

This Promising Small-Cap Biotech Stock Could Rise 70%, According to Wall Street ↗

December 15, 2023

Is the stock's risk worth the potential reward?

Via The Motley Fool

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

November 20, 2023

Via Benzinga

< Previous 1 2

...

4 5 6 7 8 9 10 11 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Vera Therapeutics, Inc. - Class A Common Stock (NQ:VERA)

All News about Vera Therapeutics, Inc. - Class A Common Stock

Resources